Stephens & Co. Reiterates Overweight on Amrize, Maintains $65 Price Target

Amrize Ltd

Amrize Ltd

AMRZ

0.00

Stephens & Co. analyst Trey Grooms reiterates Amrize (NYSE: AMRZ) with a Overweight and maintains $65 price target.